{"id":"W4412410957","doi":"10.1002/npr2.70039","title":"Primary Progressive Multiple Sclerosis: New Therapeutic Approaches","year":2025,"lang":"en","type":"review","venue":"Neuropsychopharmacology Reports","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Brandon Regional Health Authority; Winnipeg Regional Health Authority","funders":"","keywords":"Medicine; Multiple sclerosis; Remyelination; Fingolimod; Neuroprotection; Alemtuzumab; Ocrelizumab; Neuroinflammation; Glatiramer acetate; Oncology; Internal medicine; Bioinformatics; Immunology; Central nervous system; Transplantation; Myelin; Lymphoma; Inflammation; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005561612,0.001216774,0.004379872,0.0008407076,0.0002841441,0.00007163423,0.0004733421,0.0007471662,0.0003773774],"category_scores_gemma":[0.0008021002,0.0009376612,0.00139478,0.00125879,0.0004834523,0.000107992,0.000579214,0.002228421,0.0001026654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003530603,"about_ca_system_score_gemma":0.003156375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000954283,"about_ca_topic_score_gemma":0.000001381542,"domain_scores_codex":[0.993107,0.0007845336,0.001913841,0.002152002,0.0008696247,0.001173062],"domain_scores_gemma":[0.9952168,0.001118278,0.001247798,0.001516008,0.0002359334,0.0006652248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001952193,0.0006383549,0.0002561246,0.02863629,0.001875705,0.003142024,0.00004079791,5.988362e-7,0.0001741149,0.000001655105,0.04539489,0.9196442],"study_design_scores_gemma":[0.001897795,0.0002954076,0.00211737,0.01499716,0.004429581,0.002123625,0.000007011612,0.000005290604,0.00001397707,0.00001056884,0.97351,0.0005921705],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004200937,0.9804133,0.00001416977,0.0004853687,0.002716026,0.007702826,0.0000273737,0.0004335558,0.008165341],"genre_scores_gemma":[0.0001008469,0.9859902,0.0004150099,0.001422465,0.001243165,0.002459612,0.0002189919,0.0002029069,0.00794676],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9281151,"threshold_uncertainty_score":0.9993074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2308157057683825,"score_gpt":0.4032753419285918,"score_spread":0.1724596361602093,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}